Capstone Investment Advisors’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $678K | Sell |
3,700
-5,700
| -61% | -$1.05M | ﹤0.01% | 1006 |
|
|
2025
Q4 | $1.65M | Sell |
9,400
-2,800
| -23% | -$457K | ﹤0.01% | 685 |
|
|
2025
Q3 | $1.71M | Buy |
12,200
+3,200
| +36% | +$433K | ﹤0.01% | 823 |
|
|
2025
Q2 | $1.13M | Sell |
9,000
-3,600
| -29% | -$449K | ﹤0.01% | 816 |
|
|
2025
Q1 | $1.72M | Sell |
12,600
-18,800
| -60% | -$2.69M | ﹤0.01% | 722 |
|
|
2024
Q4 | $4.8M | Sell |
31,400
-4,600
| -13% | -$776K | 0.01% | 558 |
|
|
2024
Q3 | $6.98M | Buy |
36,000
+4,800
| +15% | +$1M | 0.02% | 381 |
|
|
2024
Q2 | $7.23M | Buy |
31,200
+18,500
| +146% | +$4.02M | 0.02% | 366 |
|
|
2024
Q1 | $2.74M | Sell |
12,700
-14,100
| -53% | -$3.3M | 0.01% | 649 |
|
|
2023
Q4 | $6.94M | Buy |
26,800
+7,200
| +37% | +$1.77M | 0.02% | 428 |
|
|
2023
Q3 | $5.04M | Buy |
19,600
+1,500
| +8% | +$401K | 0.02% | 427 |
|
|
2023
Q2 | $5.16M | Buy |
18,100
+200
| +1% | +$59.5K | 0.03% | 374 |
|
|
2023
Q1 | $4.98M | Sell |
17,900
-6,600
| -27% | -$1.83M | 0.03% | 363 |
|
|
2022
Q4 | $6.78M | Buy |
24,500
+900
| +4% | +$254K | 0.05% | 310 |
|
|
2022
Q3 | $6.3M | Buy |
23,600
+1,500
| +7% | +$319K | 0.04% | 349 |
|
|
2022
Q2 | $4.51M | Sell |
22,100
-29,400
| -57% | -$6.01M | 0.02% | 442 |
|
|
2022
Q1 | $10.8M | Sell |
51,500
-29,000
| -36% | -$6.31M | 0.03% | 443 |
|
|
2021
Q4 | $19.3M | Sell |
80,500
-12,600
| -14% | -$3.24M | 0.03% | 435 |
|
|
2021
Q3 | $26.3M | Buy |
93,100
+23,700
| +34% | +$7.77M | 0.05% | 345 |
|
|
2021
Q2 | $24M | Sell |
69,400
-6,200
| -8% | -$1.88M | 0.05% | 308 |
|
|
2021
Q1 | $21.1M | Buy |
75,600
+8,900
| +13% | +$2.4M | 0.06% | 286 |
|
|
2020
Q4 | $16.3M | Sell |
66,700
-25,800
| -28% | -$6.66M | 0.05% | 285 |
|
|
2020
Q3 | $26.2M | Buy |
92,500
+36,700
| +66% | +$10.2M | 0.13% | 139 |
|
|
2020
Q2 | $14.9M | Buy |
55,800
+14,100
| +34% | +$4.24M | 0.1% | 175 |
|
|
2020
Q1 | $13.2M | Sell |
41,700
-43,100
| -51% | -$13.1M | 0.21% | 86 |
|
|
2019
Q4 | $25.2M | Buy |
84,800
+1,800
| +2% | +$499K | 0.14% | 159 |
|
|
2019
Q3 | $19.3M | Buy |
83,000
+10,200
| +14% | +$2.38M | 0.13% | 144 |
|
|
2019
Q2 | $17M | Buy |
72,800
+27,900
| +62% | +$6.44M | 0.12% | 183 |
|
|
2019
Q1 | $10.6M | Buy |
44,900
+4,500
| +11% | +$1.42M | 0.1% | 199 |
|
|
2018
Q4 | $12.2M | Buy |
40,400
+9,000
| +29% | +$2.87M | 0.15% | 113 |
|
|
2018
Q3 | $11.1M | Buy |
31,400
+21,900
| +231% | +$7.54M | 0.13% | 128 |
|
|
2018
Q2 | $2.76M | Buy |
+9,500
| New | +$2.67M | 0.04% | 236 |
|
|
2017
Q1 | – | Sell |
-400
| Closed | -$113K | – | 881 |
|
|
2016
Q4 | $113K | Buy |
+400
| New | +$119K | ﹤0.01% | 858 |
|
|
2013
Q4 | – | Sell |
-5,500
| Closed | -$1.32M | – | 489 |
|
|
2013
Q3 | $1.32M | Sell |
5,500
-300
| -5% | -$67.1K | 0.01% | 395 |
|
|
2013
Q2 | $1.25M | Buy |
+5,800
| New | +$1.24M | 0.01% | 326 |
|
Other funds holding BIIB
VCM
VPM
Capstone Investment Advisors's BIIB Position: Q1 2026 in Review
Capstone Investment Advisors sold out of Biogen (BIIB) in Q1 2026, closing a stake of 2,445 shares — an estimated $451K sold.
Capstone Investment Advisors first reported a position in BIIB in Q3 2013 and held it in 33 quarters. The position peaked at $7.01M in Q1 2019. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Capstone Investment Advisors reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
- Capstone Investment Advisors sold 2,445 Biogen shares in Q1 2026, an estimated $451K.
- Capstone Investment Advisors first reported a position in Biogen in Q3 2013 and held it in 33 quarters.
- Capstone Investment Advisors's Biogen position peaked at $7.01M in Q1 2019.
- 1,003 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.